This has been a year of significant growth in achieving FCF’s mission of research, education and patient support.
RESEARCH: FCF invested over $500,000 in fellowships to scientists and physicians studying fibrolamellar. The Foundation funded innovative research that can be applied to patient treatment, and attracted multiple grant applications through a new grant application process. These research projects are in collaboration with the University of North Carolina, the American Clinical Society of Oncologists (ASCO), the Cancer Research Institute (CRI), Johns Hopkins and the International Center for Cell Therapy and Cancer Immunotherapy in Israel. We also funded previous grants to Rockefeller University and Yale.
EDUCATION AND AWARENESS: FCF’s work in 2015 extended to various US Government agencies: NIH, NCI, the Congressional Childhood Cancer Caucus and the Department of Defense. The Foundation also partnered with leading rare disease organizations focused on rare gastro-intestinal cancers. In addition, FCF worked to establish connections directly with pharmaceutical companies.
PATIENT SUPPORT: For the fourth year in a row, the very important patient and family gathering was held in Vermont. Guests arrive from all over the country to bond, share and find a community who understands.
This was also a year of strengthening and expanding FCF's internal structure, as prescribed in the Foundation's strategic plan. FCF hired a full time executive director, expanded the Board of Directors, and established a formal research grant review committee.
FCF thanks all those who donated to the Foundation to make these many achievements possible. Additionally, FCF is grateful to Stone Point Capital for providing administrative support and guidance to Foundation; and to the Charles A. and Marna Davis Foundation for covering all other administrative expenses of FCF so monies raised go directly to research.
Previously Featured stories archived here.
CONTACT US • JOIN